In future studies, we will use our humanized mouse models and samples from our ongoing Phase I clinical trial (NCT03740256) to further characterize which CAdTrio component(s) by which mechanism(s) modify the PDAC TME and influence HER2.CART anti-tumor activity. This evidence concerns the gene ERBB2 and neoplasm.